Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM-OXA induction followed by gemcitabine chemoradiotherapy in unresectable locally advanced pancreatic cancer
2005-005063-29Phase 2Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Mar 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Response rate. Started Mar 2006; status: active.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-005063-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005063-29.